4D Molecular Therapeutics
FDMT----
4D Molecular Therapeutics (FDMT)
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
4D Molecular Therapeutics Analyst Rating
View MoreForecast & Rating
Jul 21, 2026Price forecast
$28.22180.26%
Forecast & RatingBuy
11analysts
- Strong buy63.64%
- Buy18.18%
- Hold18.18%
- Sell0.00%
- Strong sell0.00%
News
- benzinga_article · Jul 20 at 08:05 AM
4D Molecular's One-Shot Eye Therapy Delivers Two-Year Win
- TradingView · Jul 20 at 07:33 AM
4D Molecular Therapeutics reports positive 2-year PRISM Phase 2b data, 78–87% reduction in injections
- PUBT · Jul 18 at 02:51 PM
4D Molecular Therapeutics posts corporate presentation highlighting 4D-150 retina gene therapy program
- StockTitan · Jul 18 at 06:15 AM
4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population | FDMT Stock News
- StockTitan · Jul 17 at 07:05 AM
4DMT Announces New Employment Inducement Grants | FDMT Stock News
- PUBT · Jul 14 at 04:05 PM
4D Molecular Therapeutics CEO David Kirn sells USD 739,829 in common shares
